·tradingview.comLow
Maxim Group initiates coverage of Nasus Pharma at Buy, sets price target at $7
Maxim Group initiated coverage of Nasus Pharma with a Buy rating and a $7 price target, implying 119.4% upside from the Oct 29 close of $3.19.
StockNYSE · US · USDHealthcare · DRUG MANUFACTURERS - GENERAL
$NSRX
Nasus Pharma Ltd
Nasus Pharma is a clinical-stage pharmaceutical company developing intranasal powder drugs for emergency medical conditions. Its proprietary Nasax platform uses powder-based nasal sprays, and its portfolio includes NS002, intranasal epinephrine for anaphylaxis; NS001, intranasal naloxone for opioid overdose, whose development is paused; and preclinical programs for intranasal midazolam, atropine and ondansetron. The company is currently a virtual company and is based in Tel Aviv, Israel. Nasus has no FDA-approved products and generates no revenue from existing products. Its business is focused on developing drug candidates and seeking regulatory approval; its stated development portfolio also includes opportunities to apply its platform to other medicines.
Price · $NSRXvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $NSRX in the last 7 days.
Insider · 30dAll trades →
No SEC Form 4 filings for $NSRX in the last 30 days.
See all $NSRX insider activity →Top stories · $NSRXMore →
·globenewswire.com
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
Nasus Pharma (NYSE: NSRX) has enrolled and dosed the first patient in a Phase 1 trial for NS003, its intranasal ondansetron formulation. Pre-clinical studies showed NS003's PK profile was comparable to IV ondansetron, with a favorable safety profile. The company aims to announce topline PK data before year-end and initiate a pivotal NS002 study for anaphylaxis in Q4. Ondansetron is widely used for chemotherapy-induced nausea and vomiting, with peak sales exceeding $1.5 billion in 2023.
·rttnews.com
Biotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains
Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.
NSRX sentiment & insider activity
Recent NSRX coverage spans financial news, technology and market movers.
What's driving NSRX
Maxim Group initiated coverage of Nasus Pharma with a Buy rating and a $7 price target, implying 119.4% upside from the Oct 29 close of $3.19.
First-in-human trial start signals progress toward potential product launch, reducing execution risk.
Regulatory clearance opens path to pivotal trial, enhancing pipeline value.
Potential short‑term stock volatility as investors assess leadership transition.
Positive cash infusion and clinical progress may support near‑term price appreciation, but net loss widening tempers upside.
AlphAI scores every news story that mentions NSRX with an AI model for sentiment and relevance, and aggregates insider trades from Nasus Pharma Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $NSRX
Score
Maxim Group initiates coverage of Nasus Pharma at Buy, sets price target at $7
Maxim Group initiated coverage of Nasus Pharma with a Buy rating and a $7 price target, implying 119.4% upside from the Oct 29 close of $3.19.
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
Nasus Pharma (NYSE: NSRX) has enrolled and dosed the first patient in a Phase 1 trial for NS003, its intranasal ondansetron formulation. Pre-clinical studies showed NS003's PK profile was comparable to IV ondansetron, with a favorable safety profile. The company aims to announce topline PK data before year-end and initiate a pivotal NS002 study for anaphylaxis in Q4. Ondansetron is widely used for chemotherapy-induced nausea and vomiting, with peak sales exceeding $1.5 billion in 2023.
Biotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains
Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.
Nasus Pharma, Ltd.: Nasus Pharma Announces Transition of Chief Financial Officer
Nasus Pharma Ltd. (NSRX) announced CFO Eyal Rubin's departure to pursue a new opportunity. Rubin will stay until September 18, 2026, to ensure a smooth transition. Oren Elmaliach, Director of Finance, has been appointed Interim CFO. Elmaliach has extensive financial experience and knowledge of the company's operations.
Nasus Pharma Ltd (NSRX): Financial results for H1 2026
Nasus Pharma Ltd (NSRX) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update Appointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, August
Teleman Dan Benjamin purchased $20K of NSRX
Teleman Dan Benjamin (Chief Executive Officer) purchased 6,550 shares of Nasus Pharma Ltd (NSRX) at $3.10 on 2026-06-17.
Nasus Pharma to Participate in Upcoming Investor Conferences
Nasus Pharma, a clinical-stage pharmaceutical company, announced its participation in two upcoming investor conferences in May 2026. CFO Eyal Rubin will attend the "Market Movers Investor Summit" and the "D. Boral Capital Global Conference" in New York, engaging in one-on-one meetings with interested investors. The company focuses on developing innovative intranasal products, including NS002, an intranasal epinephrine product for anaphylaxis.
Funicular Funds, Cable Car Capital stake 5.2% in Nasus Pharma (NSRX)
Funicular Funds, Cable Car Capital, and Jacob Ma-Weaver have collectively reported a 5.2% beneficial ownership stake in Nasus Pharma Ltd (NSRX), totaling 612,913 Ordinary Shares each. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment. The ownership calculation is based on 11,710,808 shares outstanding as of March 27, 2026.
Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer - Nasus Pharma (AMEX:NSRX)
TEL AVIV, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Nasus Pharma Ltd. ( NYSE:NSRX ) ( "Nasus Pharma", "Nasus" or the "Company" ) , a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment ...
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed - Nasus Pharma (AMEX:NSRX)
The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can achieve faster and higher absorption of epinephrine compared to an autoinjector